Pain Therapeutics Announces 2009 Financial Results, Outlines Business Priorities

Jan 28, 2010

- $176 Million of Cash, No Debt -

- Cash Requirement in 2010 Under $10 Million -

- REMOXY® NDA Resubmission Still Anticipated in 2010 -

SAN MATEO, Calif., Jan. 28, 2010 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today reported financial results for the year ended December 31, 2009, provided an update on its cash position and outlined its business strategy for maintaining financial strength in 2010.

Net loss for 2009 was $3.5 million, or $0.08 per share, compared to net income of $15.3 million, or $0.35 per share, for 2008. 

At December 31, 2009, Pain Therapeutics had cash, cash equivalents and marketable securities of $175.8 million, or about $4.16 per share, no debt and approximately 42.3 million shares outstanding. We expect our cash requirements in 2010 to be under $10.0 million.

“We think our business model is performing well,” said Remi Barbier, Pain Therapeutics’ chairman, president and chief executive officer. “We continue to operate the business with discipline, to focus on innovation and to advance our pipeline. These are also core elements of our business strategy for 2010. We’re a small company taking on some of the toughest challenges in medical research, yet with a REMOXY NDA resubmission within sight and new hematology/oncology data coming this quarter, we think we’re positioned to win in 2010.”

REMOXY in 2010

Pain Therapeutics remains committed to the regulatory success of REMOXY, our lead drug candidate. REMOXY is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. REMOXY and other abuse-resistant painkillers are being developed pursuant to a strategic alliance we have with King Pharmaceuticals, Inc. We believe REMOXY represents the rare combination of a well-partnered, late-stage drug asset with a unique profile, and whose clinical efficacy has been substantially de-risked.

  • Pursuant to the terms of the strategic alliance, King funds our development expenses incurred by us for REMOXY and three other abuse-resistant pain medications.
  • From 2005 to 2008, we and King jointly managed a Phase III clinical program and New Drug Application (NDA) for REMOXY. In mid-2008, the U.S. Food and Drug Administration (FDA) accepted an NDA for REMOXY with Priority Review.
  • In December 2008, we received from the FDA a Complete Response Letter which indicated additional non-clinical data is required to support the approval of REMOXY. The FDA has not requested or recommended additional clinical efficacy studies prior to approval.
  • In March 2009, King assumed sole responsibility for the regulatory approval of REMOXY. This shift of responsibility does not change the economic terms of our strategic alliance with King.
  • In July 2009, King met with the FDA to discuss REMOXY. As a result of this meeting, King anticipates a resubmission of the REMOXY NDA in 2010.
  • Upon FDA approval of REMOXY, we will receive a $15.0 million cash milestone payment and a running royalty equal to 20% of net sales of drugs developed under this strategic alliance, except as to the first $1.0 billion in cumulative net sales, which royalty is set at 15%.
  • To date, King has made milestone payments to us of $25.0 million. We could receive from King up to $125.0 million in additional milestone payments in the course of the clinical and regulatory development of REMOXY and three other abuse-resistant pain medications.

Hematology/Oncology in 2010

Our corporate strategy is to spend carefully but to keep innovation at the top of our agenda. In 2009, we made disciplined investments in two important disease areas -- hemophilia and melanoma.  We expect to announce new data in both disease areas in Q1 2010. We own commercial rights to all of our drug candidates in hematology/oncology.

  • A radio-labeled monoclonal antibody program, developed at Albert Einstein College of Medicine, is aimed at treating patients with late-stage (metastatic) melanoma. This drug candidate is called PTI-188.
  • In Q4 2009, we completed enrollment in our second Phase I study in Israel with PTI-188. In this study, researchers treated three cohorts of patients with metastatic melanoma using PTI-188.
  • We have a gene transfer program, developed at Stanford University, aimed at correcting an underlying genetic defect in patients with hemophilia. Importantly, no viral vector is utilized.
  • In Q4 2009, we completed a pre-clinical study with our gene transfer technology.

2009 Financial Results

  • Collaboration revenue for 2009 was $6.2 million, compared to $29.4 million for 2008, and reflects reimbursement of our development expenses under our strategic alliance with King.
  • Research and development expenses for 2009 decreased to $21.1 million from $45.8 million for 2008. This decrease was mostly due to decreased spending by us for REMOXY and other abuse-resistant product candidates under our strategic alliance with King, as well as lower non-cash stock-related compensation. Research and development expenses included non-cash stock-related compensation of $4.0 million for 2009 and $6.1 million for 2008.
  • General and administrative expenses for 2009 decreased to $6.3 million from $9.2 million for 2008. This decrease was mostly due to lower non-cash equity related costs as well as lower operating costs. General and administrative expenses included non-cash stock-related compensation of $2.7 million for 2009 and $4.1 million for 2008.
  • Interest income for 2009 decreased to $1.8 million from $6.0 million for 2008. This decrease was mostly due to decreases in interest rates on our investments in marketable securities.

About Pain Therapeutics, Inc.

Pain Therapeutics, Inc. is a biopharmaceutical company that develops novel drugs. Our lead drug candidate, REMOXY, is a strong painkiller with a unique formulation designed to reduce potential risks of unintended use. We are also developing novel drugs in the area of hematology/oncology. We have in clinical development a monoclonal antibody to treat metastatic melanoma, a deadly form of skin cancer. We also have in pre-clinical development a drug candidate to treat hemophilia, a genetic disorder in which patients are unable to stop bleeding. The FDA has not approved any of our drug candidates for commercial sale. For more information, please visit

Note Regarding Forward-Looking Statements: This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Pain Therapeutics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, any statements relating to the timing of King’s resubmission of the NDA for REMOXY in 2010; our cash requirements for 2010; expected timing of announcements regarding clinical trials and non-clinical studies; our expected receipt of milestone payment or other revenue under our collaboration with King, including reimbursement of our ongoing development activities under the collaboration with King; and the benefits of our drug candidate, REMOXY, including statements concerning its clinical efficacy. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in obtaining regulatory approval of our drug candidates, unexpected adverse side effects or inadequate therapeutic efficacy of our drug candidates (including the risk that current and past results of clinical trials are not necessarily indicative of future results of clinical trials), unanticipated additional research and development and other costs and the timing and receipt of funds from our commercial partner, potential disputes arising with our strategic partners, potential claims of violating the patent rights of third parties, the uncertainty of patent protection for our intellectual property or trade secrets, and the potential for abuse and misuse resistant pain medications to be developed by competitors and potential competitors. For further information regarding these and other risks related to our business, investors should consult our filings with the Securities and Exchange Commission.


(in thousands, except per share amounts)
  Three Months Ended December 31, Year Ended December 31,  
  2009 2008 2009 2008  
Collaboration revenue $142 $4,658 $6,215 $29,377  
Program fee revenue 3,587 3,587 14,348 14,348  
Milestone revenue -- -- -- 20,000  
Total revenue 3,729 8,245 20,563 63,725  
Operating expenses          
Research and development 3,811 9,190 21,059 45,817  
General and administrative 1,584 1,927 6,258 9,196  
Total operating expenses 5,395 11,117 27,317 55,013  
Operating income (loss) (1,666) (2,872) (6,754) 8,712  
Interest income 544 866 1,777 6,018  
Income (loss) before income taxes (1,122) (2,006) (4,977) 14,730  
Benefit from income taxes (825) (617) (1,510) (617)  
Net income (loss) $(297) $(1,389) $(3,467) $15,347  
Net income (loss) per share          
Basic $(0.01) $(0.03) $(0.08) $0.36  
Diluted $(0.01) $(0.03) $(0.08) $0.35  
Weighted-average shares used in computing
net income (loss) per share  
Basic 42,275 42,044 42,165 42,252  
Diluted 42,275 42,044 42,165 43,857  


  December 31,
  2009 2008(1)
Current assets    
Cash, cash equivalents and marketable securities $175,759 $190,095
Other current assets 2,712 541
Total current assets 178,471 190,636
Non-current assets    
Property and equipment, net 517 774
Other assets 3,017 2,026
Total assets $182,005 $193,436
Liabilities and stockholders' equity    
Current liabilities    
Accounts payable and accrued development expenses $2,538 $3,245
Deferred program fee revenue - current portion 14,348 14,348
Other accrued liabilities 1,625 2,521
Total current liabilities 18,511 20,114
Non-current liabilities    
Deferred program fee revenue - non-current portion 53,805 68,154
Other liabilities 1,437 882
Total liabilities 73,753 89,150
Stockholders' equity    
Common stock 42 42
Additional paid-in-capital 225,432 218,021
Accumulated other comprehensive income 347 325
Accumulated deficit (117,569) (114,102)
Total stockholders' equity 108,252 104,286
Total liabilities and stockholders' equity $182,005 $193,436

Derived from the Company’s annual financial Statements as of December 31, 2008, included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission.



CONTACT: Pain Therapeutics, Inc.
         Judy Ishida, Administrative Manager

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.